Published in Can Med Assoc J on June 07, 1975
An improved procedure for serum creatine phosphokinase determination. J Lab Clin Med (1967) 6.12
An accurate, clinically practical system for spatial vectorcardiography. Circulation (1956) 5.32
Exercise testing of patients with coronary heart disease. Principles and normal standards for evaluation. Ann Clin Res (1971) 4.04
Exercise stress testing in evaluation of patients with ischemic heart disease. Prog Cardiovasc Dis (1969) 3.15
Exercise tests. A survey of procedures, safety, and litigation experience in approximately 170,000 tests. JAMA (1971) 2.82
Reduction of alpha-ketobutyrate by human serum. Nature (1960) 2.56
Use of exercise testing for diagnostic and functional evaluation of patients with arteriosclerotic heart disease. Circulation (1971) 1.72
Changes in serum enzyme levels after exercise in trained and untrained subjects. J Appl Physiol (1962) 1.59
Creatine kinase and glutamic oxalacetic transaminase activity in serum: kinetics of change with exercise and effect of physical conditioning. J Lab Clin Med (1968) 1.12
Exercise-induced ventricular arrhythmias in patients with coronary artery disease. Their relation to angiographic findings. Am J Cardiol (1973) 1.06
Maximum treadmill exercise test in patients with abnormal control electrocardiograms. Circulation (1974) 1.01
Serum enzyme levels during exercise in patients with coronary heart disease: effects of training. Am Heart J (1972) 1.01
Exercise electrocardiogram patterns in normal women. Br Heart J (1973) 0.99
Enzyme blood levels and water balance during a marathon race. J Appl Physiol (1974) 0.90
Revised spectrophotometric methods for the determination of glutamic-oxalacetic transaminase, glutamic-pyruvic transaminase, and lactic acid dehydrogenase. Tech Bull Regist Med Technol (1960) 0.86
Changes in serum creatine phosphokinase during submaximal exercise testing. Can Med Assoc J (1973) 0.81
Quantitative electrophoretic determination of lactate dehydrogenase isoenzymes. Tech Bull Regist Med Technol (1966) 0.78
Peripheral beta-adrenergic receptors concerned with tremor. Clin Sci (1967) 2.97
Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects. J Clin Pharmacol (1983) 1.76
The effect of chronic adrenergic receptor blockade on plasma renin activity in man. J Clin Endocrinol Metab (1972) 1.75
Effect of beta-adrenergic blockade on finger tremor and Achilles reflex time in anxious and thyrotoxic patients. Acta Endocrinol (Copenh) (1968) 1.48
Suppression of essential tremor by propranolol: correlation of effect with drug plasma levels and intensity of beta-adrenergic blockade. Ann Neurol (1977) 1.36
Fulminant beriberi heart disease with lactic acidosis: presentation of a case with evaluation of left ventricular function and review of pathophysiologic mechanisms. Circulation (1978) 1.30
Propranolol therapy during pregnancy, labor, and delivery: evidence for transplacental drug transfer and impaired neonatal drug disposition. J Pediatr (1977) 1.28
The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther (1982) 1.21
Effects of nifedipine on esophageal motor function in humans: correlation with plasma nifedipine concentration. Gastroenterology (1984) 1.05
Clinical pharmacokinetics of verapamil. Clin Pharmacokinet (1984) 1.05
Influence of severity of ventricular dysfunction on hemodynamic responses to intravenously administered verapamil in ischemic heart disease. Am J Cardiol (1981) 1.04
Reversal of the cardiovascular effects of verapamil by calcium and sodium: differences between electrophysiologic and hemodynamic responses. Circulation (1979) 0.99
Failure of single-session dietary counseling to reduce salt intake in hypertensive patients. South Med J (1977) 0.99
Effect of adrenergic receptor blockade on the responses to isometric handgrip: studies in normal and hypertensive subjects. J Cardiovasc Pharmacol (1980) 0.96
Oral insulin product hexyl-insulin monoconjugate 2 (HIM2) in type 1 diabetes mellitus: the glucose stabilization effects of HIM2. Diabetes Technol Ther (2002) 0.95
The pharmacology of verapamil. V. Tissue distribution of verapamil and norverapamil in rat and dog. Pharmacology (1983) 0.95
Hemodynamic consequences of combined beta-adrenergic and slow calcium channel blockade in man. Circulation (1982) 0.94
Kinetics and dynamics of nifedipine after oral and sublingual doses. Am J Med (1986) 0.92
Measurement of nifedipine in plasma by gas--liquid chromatography and electron-capture detection. Clin Chem (1983) 0.92
Clinical pharmacology of slow channel blocking agents. Prog Cardiovasc Dis (1982) 0.89
Clinical pharmacokinetics of calcium channel antagonists. J Cardiovasc Pharmacol (1982) 0.89
Intravenous verapamil for termination of re-entrant supraventricular tachycardias: intracardiac studies correlated with plasma verapamil concentrations. Ann Intern Med (1980) 0.89
Electrophysiologic and hemodynamic effects of verapamin. Correlation with plasma drug concentrations. Circulation (1978) 0.89
Malignant hypertension: effect of therapy on renin and aldosterone. Circ Res (1971) 0.88
Effect of nifedipine on gastric emptying in normal subjects. Dig Dis Sci (1985) 0.87
Fluorometric assay of verapamil in biological fluids and tissues. J Pharm Sci (1976) 0.87
Plasma renin activity in chronic plumbism. Effect of treatment. Arch Intern Med (1971) 0.87
Efficacy of verapamil in exercise-induced ventricular tachycardia. Am J Cardiol (1985) 0.86
Improving the effect of FDA-mandated drug safety alerts with Internet-based continuing medical education. Curr Drug Saf (2013) 0.85
Intravenous propranolol administration: a method for rapidly achieving and sustaining desired plasma levels. Clin Pharmacol Ther (1976) 0.84
Tricuspid regurgitation following inferior myocardial infarction. Arch Intern Med (1976) 0.83
Pharmacokinetics of calcium-entry blockers. Am J Cardiol (1985) 0.83
Verapamil plasma levels and ventricular rate response in patients with atrial fibrillation and flutter. Clin Pharmacol Ther (1979) 0.83
Macroglossia--a positional complication. Anesthesiology (1974) 0.82
Effects of hemodynamic changes on the elimination kinetics of verapamil and nifedipine. J Pharmacol Exp Ther (1984) 0.82
Peripheral beta-receptor responsiveness in patients with essential hypertension. Arch Intern Med (1979) 0.82
Effect of hypothermia on drug metabolism. In vitro studies with propranolol and verapamil. Pharmacology (1980) 0.81
Effects of hypothermia on propranolol kinetics. Clin Pharmacol Ther (1979) 0.81
Verapamil-induced changes in central conduction in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (1985) 0.81
Studies of experimental cervical spinal cord transection. Part II: Plasma norepinephrine levels after acute cervical spinal cord transection. J Neurosurg (1979) 0.81
GLC determination of probenecid in biological fluids. J Pharm Sci (1973) 0.80
Age-related changes in drug handling in man. Am J Cardiol (1986) 0.79
Malignant hypertension due to renal artery stenosis. Greater renin release from the nonstenotic kidney. JAMA (1972) 0.79
Correlation of plasma levels of nifedipine and cardiovascular effects after sublingual dosing in normal subjects. J Clin Pharmacol (1985) 0.79
The pharmacology of verapamil. III. Pharmacokinetics in normal subjects after intravenous drug administration. J Cardiovasc Pharmacol (1981) 0.79
Fever, tachycardia, and hypertension with acute catatonic schizophrenia. Arch Intern Med (1978) 0.78
The pharmacology of verapamil. I. Elimination kinetics in dogs and correlation of plasma levels with effect on the eletrocardiogram. J Pharmacol Exp Ther (1977) 0.78
Studies of experimental cervical spinal cord transection. Part IV: Effects of cervical spinal cord transection on myocardial blood flow in anesthetized dogs. J Neurosurg (1980) 0.78
Studies of experimental cervical spinal cord transection. Part III: Effects of acute cervical spinal cord transection on cerebral blood flow. J Neurosurg (1979) 0.77
Effect of intravenous furosemide on the renal excretion of digoxin. J Clin Pharmacol (1976) 0.77
The effects of verapamil and lidocaine on the automatic depolarizations in guinea-pig ventricular myocardium. J Pharmacol Exp Ther (1978) 0.77
Measurement of verapamil concentrations in plasma by gas chromatography and high pressure liquid chromatography. Ther Drug Monit (1980) 0.77
Absence of slow channel-dependent conduction within the His-Purkinje (bundle branch) reentrant circuit: a clinical and experimental study of the effects of verapamil. Am J Cardiol (1982) 0.77
Effects of intravenous and oral verapamil upon pressor and adrenal steroidogenic responses in normal man. J Clin Endocrinol Metab (1983) 0.76
Cardiovascular and pharmacokinetic consequences of combined administration of verapamil and propranolol in dogs. Am J Cardiol (1985) 0.76
Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas. An Illinois Cancer Center study. Invest New Drugs (1992) 0.76
Effect of verapamil on retrograde conduction in atrioventricular nodal reentrant tachycardia. Am J Cardiol (1984) 0.76
Aspects of the clinical pharmacology of verapamil, a calcium-entry antagonist. Biopharm Drug Dispos (1983) 0.75
Phase II trial of caracemide (NSC 253272) in advanced unresectable non-small cell bronchogenic carcinoma. An Illinois Cancer Council study. Invest New Drugs (1992) 0.75
Effect of beta-adrenergic blockade on hypothermia-induced hypokalemia. Surg Forum (1977) 0.75
Aspects of the clinical pharmacology of nifedipine, a dihydropyridine calcium-entry antagonist. Biopharm Drug Dispos (1986) 0.75
Chronic salt excess and hypertension. A cultural epidemic. J Tenn Med Assoc (1971) 0.75
Kinetics and dynamics of calcium entry antagonists in systemic hypertension. Am J Cardiol (1986) 0.75
Effects of antihypertensive drug therapy on responses to isometric exercise. South Med J (1981) 0.75
Particle size distribution of radium-containing phosphor powders. Health Phys (1973) 0.75
Program for cardiac patients: stress testing and training. Phys Ther (1976) 0.75
Studies of experimental cervical spinal cord transection. Part I: Hemodynamic changes after acute cervical spinal cord transection. J Neurosurg (1978) 0.75
Contrasting effects of verapamil and procainamide on intraventricular conduction and reentry within the His-Purkinje system in man. Acta Cardiol (1982) 0.75
Painless myocardial infarctions after coronary bypass operation. South Med J (1974) 0.75
Hemodynamic and pharmacokinetic aspects of the interactions between verapamil and pindolol. Pharmacology (1987) 0.75
Cardiodepressant actions of combined diltiazem and propranolol in dogs. J Cardiovasc Pharmacol (1994) 0.75
Serum concentrations of ampicillin and probenecid and ampicillin excretion after repeated oral administration of a pivampicillin-probenecid salt (MK-356). Eur J Clin Pharmacol (1975) 0.75
Effects of verapamil on the arrhythmogenic action of acetylstrophanthidin. Pharmacology (1984) 0.75
A multicenter comparison of isradipine and prazosin for treatment of essential hypertension. Cardiovasc Drugs Ther (1990) 0.75
Medical admissions to a teaching service: a six months' review in a veterans hospital. South Med J (1974) 0.75
Effects of phenobarbital and SKF-525A on in vitro hepatic metabolism of verapamil and nifedipine. Pharmacology (1985) 0.75
Hypertensive crisis and myocardial infarction after fluorescein angiography. South Med J (1981) 0.75
Nifedipine stability in cardioplegic solution. Am J Hosp Pharm (1984) 0.75
Pharmacodynamic comparison of verapamil and nifedipine in anesthetized dogs. J Cardiovasc Pharmacol (1985) 0.75
Hypertension and neurofibromatosis. Case report. Hypertension (1983) 0.75
GLC assay of verapamil in plasma: identification of fluorescent metabolites after oral drug administration. J Pharm Sci (1979) 0.75
Plasma concentrations and hemodynamic effects of nifedipine: a study in anesthetized dogs. J Cardiovasc Pharmacol (1984) 0.75
Suppression of essential tremor by propranolol: correlation of effect with intensity of beta-adrenergic blockade. Trans Am Neurol Assoc (1976) 0.75
Clinical implications of patient-provider agreements in opioid prescribing. Curr Drug Saf (2015) 0.75
Pharmacology of verapamil. II. Impairment of glucose tolerance by verapamil in the conscious dog. Pharmacology (1980) 0.75
Nifedipine-propranolol interaction: dependence of cardiovascular effects on plasma drug concentrations. J Cardiovasc Pharmacol (1987) 0.75
Identification of central trigeminal nociceptors and the effects of nitrous oxide. Anesthesiology (1973) 0.75
Obstetric anesthesia--a two-way street. JOGN Nurs (1976) 0.75
Effect of hypothyroidism on parasitemia and survival in rodent malaria. Am J Med Sci (1974) 0.75
Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council Study. Invest New Drugs (1989) 0.75
Endocarditis on prosthetic mitral valves. Fatal obstruction to left ventricular inflow. Chest (1974) 0.75
Electron-capture GLC determination of a new antiarrhythmic agent, alpha,alpha-dimethyl-4-(alpha,alpha,beta,beta-tetrafluorophenethyl) benzylamine, in biological fluids. J Pharm Sci (1975) 0.75
The use of exercise in diagnosis and treatment of cardiac patients in a community hospital: experience over 27 months. J Ky Med Assoc (1976) 0.75
Guanethidine in antihypertensive therapy: experience with an oral loading regimen. J Clin Pharmacol (1976) 0.75
Negative inotropic effect of intravenous nifedipine in coronary artery disease: relation to plasma levels. Am Heart J (1990) 0.75
The possible role of antiarrhythmic drugs in the prevention of sudden death. Heart Lung (1973) 0.75